New drug aims to ease heavy periods caused by fibroids
NCT ID NCT07378098
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial tests whether the experimental drug KLH-2109 can reduce heavy menstrual bleeding in people with uterine fibroids. About 254 participants will take either KLH-2109 or a standard treatment for 24 weeks, tracking their bleeding and visiting the clinic for safety checks. The main goal is to see if KLH-2109 lowers bleeding enough to improve quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
KLH-2109 (a drug taken as a pill)
What this could lead to
If successful, this could offer a new non-surgical option to reduce heavy bleeding in people with uterine fibroids.
What could go wrong
This is still an early Phase 3 trial with 254 participants. The drug may not prove more effective than existing treatments, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UTERINE FIBROIDS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Asan Medical Center
RECRUITINGSeoul, South Korea
Contact Phone: •••-•••-••••